Advantage Alpha Capital Partners’s Amedisys AMED Stock Holding History

Advantage Alpha Capital Partners’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-61,848	Closed	-$4.55M	–	90
2023 Q1	$4.55M	Sell	61,848 -12,571	-17%	-$1.09M	0.95%	47
2022 Q4	$6.22M	Sell	74,419 -3,872	-5%	-$349K	1.26%	29
2022 Q3	$7.58M	Buy	78,291 +7,208	+10%	+$860K	1.39%	29
2022 Q2	$7.47M	Buy	71,083 +17,403	+32%	+$2.22M	1.29%	38
2022 Q1	$9.25M	Sell	53,680 -9,878	-16%	-$1.48M	1.38%	16
2021 Q4	$10.3M	Buy	63,558 +13,020	+26%	+$2.09M	1.47%	15
2021 Q3	$7.54M	Buy	50,538 +40,580	+408%	+$8.44M	1.37%	22
2021 Q2	$2.44M	Buy	+9,958	New	+$2.61M	0.47%	86

Other funds holding AMED

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Advantage Alpha Capital Partners's AMED Position: Q2 2023 in Review

Advantage Alpha Capital Partners sold out of Amedisys (AMED) in Q2 2023, closing a stake of 61,848 shares — an estimated $4.55M sold.

Advantage Alpha Capital Partners first reported a position in AMED in Q2 2021 and held it in 8 quarters. The position peaked at $10.3M in Q4 2021. 300 funds tracked by Wall St. Rank hold AMED as of Q2 2023.

Advantage Alpha Capital Partners reported no remaining Amedisys position as of Q2 2023 after selling out during the quarter.
Advantage Alpha Capital Partners sold 61,848 Amedisys shares in Q2 2023, an estimated $4.55M.
Advantage Alpha Capital Partners first reported a position in Amedisys in Q2 2021 and held it in 8 quarters.
Advantage Alpha Capital Partners's Amedisys position peaked at $10.3M in Q4 2021.
300 funds tracked by Wall St. Rank held Amedisys as of Q2 2023.

Based on Advantage Alpha Capital Partners's 13F filing for Q2 2023, filed 14 Aug 2023.